Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

  • Showing results for d. scit. Your search for D. Sciti retrieved no results.
1.

Social cognition and interaction training for recent-onset schizophrenia: A preliminary randomized trial.

Rocha NB, Campos C, Figueiredo JM, Saraiva S, Almeida C, Moreira C, Pereira G, Telles-Correia D, Roberts D.

Early Interv Psychiatry. 2020 Feb 12. doi: 10.1111/eip.12944. [Epub ahead of print]

PMID:
32052567
3.

Clinical aspects of sublingual immunotherapy tablets and drops.

Tankersley M, Han JK, Nolte H.

Ann Allergy Asthma Immunol. 2020 Jan 7. pii: S1081-1206(19)31532-7. doi: 10.1016/j.anai.2019.12.025. [Epub ahead of print] Review.

PMID:
31923544
4.

Perspectives in allergen immunotherapy: 2019 and beyond.

Pfaar O, Agache I, de Blay F, Bonini S, Chaker AM, Durham SR, Gawlik R, Hellings PW, Jutel M, Kleine-Tebbe J, Klimek L, Kopp MV, Nandy A, Rabin RL, van Ree R, Renz H, Roberts G, Salapatek AM, Schmidt-Weber CB, Shamji MH, Sturm GJ, Virchow JC, Wahn U, Willers C, Zieglmayer P, Akdis CA.

Allergy. 2019 Dec;74 Suppl 108:3-25. doi: 10.1111/all.14077. Review.

PMID:
31872476
5.

Clinical assessment of tolerability, immunological and cutaneous reactivity effects of an abbreviated schedule with Olea europaeanative extract of subcutaneous immunotherapy.

Saenza De San Pedro B, Mur MP, Valverde L, Gonzalo Garijo MA, Hernandez M, Madariaga B, Asturias JA, Begona L, Martinez A, Gomez Fernandez M.

Eur Ann Allergy Clin Immunol. 2019 Nov 27. doi: 10.23822/EurAnnACI.1764-1489.124. [Epub ahead of print]

PMID:
31789492
6.

Success factors for adherence in hyposensitization.

Sondermann N, Shah-Hosseini K, Henkel K, Schwalfenberg A, Mösges R.

Allergol Select. 2018 Sep 1;2(1):89-93. doi: 10.5414/ALX01430E. eCollection 2018.

7.

Immunotherapy for house-dust mite allergy.

Nelson HS.

Allergy Asthma Proc. 2018 Jul 1;39(4):264-272. doi: 10.2500/aap.2018.39.4145.

PMID:
30095391
8.

Cost of subcutaneous immunotherapy in a large insured population in the United States.

Mao J, Heithoff KA, Koep E, Murphy T, Hammerby E.

Curr Med Res Opin. 2019 Feb;35(2):351-358. doi: 10.1080/03007995.2018.1510386. Epub 2018 Sep 12.

PMID:
30091647
9.

Functional and Immunoreactive Levels of IgG4 Correlate with Clinical Responses during the Maintenance Phase of House Dust Mite Immunotherapy.

Feng M, Su Q, Lai X, Xian M, Shi X, Wurtzen PA, Qin R, Zeng X, Li J.

J Immunol. 2018 Jun 15;200(12):3897-3904. doi: 10.4049/jimmunol.1701690. Epub 2018 May 4.

10.

Successful transdermal allergen delivery and allergen-specific immunotherapy using biodegradable microneedle patches.

Kim JH, Shin JU, Kim SH, Noh JY, Kim HR, Lee J, Chu H, Jeong KY, Park KH, Kim JD, Kim HK, Jeong DH, Yong TS, Park JW, Lee KH.

Biomaterials. 2018 Jan;150:38-48. doi: 10.1016/j.biomaterials.2017.10.013. Epub 2017 Oct 4.

PMID:
29032329
11.

The efficacy of oral and subcutaneous antigen-specific immunotherapy in murine cow's milk- and peanut allergy models.

Vonk MM, Wagenaar L, Pieters RHH, Knippels LMJ, Willemsen LEM, Smit JJ, van Esch BCAM, Garssen J.

Clin Transl Allergy. 2017 Sep 29;7:35. doi: 10.1186/s13601-017-0170-y. eCollection 2017.

12.

Compliance with allergen immunotherapy and factors affecting compliance among patients with respiratory allergies.

Musa F, Al-Ahmad M, Arifhodzic N, Al-Herz W.

Hum Vaccin Immunother. 2017 Mar 4;13(3):514-517. doi: 10.1080/21645515.2016.1243632. Epub 2016 Nov 7.

13.

Birch pollen immunotherapy inhibits anaphylaxis to the cross-reactive apple allergen Mal d 1 in mice.

Utsch L, Logiantara A, Wallner M, Hofer H, van Ree R, van Rijt LS.

Clin Exp Allergy. 2016 Nov;46(11):1474-1483. doi: 10.1111/cea.12775. Epub 2016 Aug 8.

PMID:
27376790
14.

Different Responses in Induction of Allergen Specific Immunoglobulin G4 and IgE-Blocking Factors for Three Mite Subcutaneous Immunotherapy Products.

Park KH, Lee SC, Son YW, Jeong KY, Shin YS, Shin JU, Sim da W, Park HJ, Lee JH, Lee KH, Park JW.

Yonsei Med J. 2016 Nov;57(6):1427-34. doi: 10.3349/ymj.2016.57.6.1427.

15.

Allergen immunotherapy now and in the future.

Nelson HS.

Allergy Asthma Proc. 2016 Jul;37(4):268-72. doi: 10.2500/aap.2016.37.3966. Review.

PMID:
27401313
16.

Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.

Canonica GW, Virchow JC, Zieglmayer P, Ljørring C, Smith IM, Mosbech H.

Expert Rev Clin Immunol. 2016 Aug;12(8):805-15. doi: 10.1080/1744666X.2016.1200467. Epub 2016 Jul 1. Review.

PMID:
27322777
17.

New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIREs).

Klimek L, Pfaar O, Worm M.

Expert Rev Clin Immunol. 2016 Oct;12(10):1123-35. doi: 10.1080/1744666X.2016.1189825. Epub 2016 Jun 13. Review.

PMID:
27191353
18.

Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients.

Soyyigit S, Guloglu D, Ikinciogullari A, Secil D, Oztuna D, Mungan D, Misirligil Z, Sin BA.

Ann Allergy Asthma Immunol. 2016 Mar;116(3):244-251.e2. doi: 10.1016/j.anai.2016.01.002.

PMID:
26945497
19.

Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark.

Rønborg S, Johnsen CR, Theilgaard S, Winther A, Hahn-Pedersen J, Andreasen JN, Olsen J.

J Med Econ. 2016 Aug;19(8):735-41. doi: 10.3111/13696998.2016.1158718. Epub 2016 Mar 16.

PMID:
26909663
20.

Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial.

Klimek L, Bachert C, Lukat KF, Pfaar O, Meyer H, Narkus A.

Clin Transl Allergy. 2015 Aug 3;5:28. doi: 10.1186/s13601-015-0071-x. eCollection 2015.

Supplemental Content

Loading ...
Support Center